Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
The decision to discontinue was based on data from pre-planned analyses of the phase 3 PIVOT-09 study and the phase 2 PIVOT-10 study.
Oncology
Anxiety, Depression Med Use Linked to Increased Odds of PSA Testing
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
Bladder-Sparing Therapies for Localized Muscle-Invasive Bladder Cancer Compared
The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.
E-Cigarette Smoking History Tied to Increased Bladder, Lung Cancer Risk
Findings demonstrated that all smoking histories were tied to a higher prevalence of bladder and lung cancer.
Sacituzumab Govitecan Plus Pembrolizumab Promising for Metastatic Urothelial Cancer After Failure With Platinum-Based Regimen
Cohort 3 of the phase 2 TROPHY-U-01 trial evaluated sacituzumab govitecan plus pembrolizumab in checkpoint inhibitor-naive adults with metastatic urothelial cancer who progressed after platinum-based chemotherapy.
Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
Immune Checkpoint Inhibitor Combo Therapy Assessed in mRCC Patients With Poor Performance Status
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
Pembrolizumab Plus Lenvatinib Not Superior to Pembrolizumab Alone in Advanced Urothelial Carcinoma
The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma.
Continued Enzalutamide Tx Beneficial in mCRPC Patients With Progressive Disease
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
Statin Use Not Associated With Survival Benefits in mCRPC Patients
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...